PAIP2B (poly(A) binding protein interacting protein 2B) is a translational repressor that inhibits cap-dependent mRNA translation by displacing PABPC1 from the poly(A) tail 1. Like its homolog PAIP2A, PAIP2B contains conserved PABP-binding domains and functions to decrease PABP affinity for polyadenylated RNA, thereby disrupting the synergistic translation enhancement normally mediated by 5' cap-3' poly(A) tail interactions 1. PAIP2B does not affect IRES-mediated translation, indicating mechanism specificity 1. Unlike PAIP2A, PAIP2B exhibits lower ubiquitination rates and slower proteasomal degradation, suggesting distinct tissue-specific regulation 1. Clinically, PAIP2B variants associate with disease susceptibility: intronic SNP rs113988120 confers 3.06-fold increased pancreatic cancer mortality risk 2, and reduced PAIP2B expression occurs in pancreatic tumors versus normal tissue 2. Additionally, PAIP2B variants correlate with antipsychotic-induced involuntary movements in schizophrenia patients 3, and height-related PAIP2B variants inversely associate with metabolic syndrome risk 4. PAIP2B emerged as prognostically significant in hepatocellular carcinoma competing endogenous RNA networks 5. These findings suggest PAIP2B functions as a potential tumor suppressor and therapeutic target across multiple cancer types.